Table 1. Clinical trial characteristics.

No.a	Vector	T cell Original	Cell culture	Transfection method	T Cell treatment	CAR T cell persistence	Diagnosis	Lymphodepletion	Doseb	Response	Ref
2	IgG-CD4+ CD3	autologous	3 month	Electroporation	OKT3 + IL-2 +irradiated LCL feeders	1 day	lymphoma	Fludarabine IL-2	108−109/m2	2PD	9
1	CD28+ CD28 and CD3	autologous	18-26 day	Lentivirus	OKT3 + IL-2 +irradiated LCL feeders	36 weeks	lymphoma	Cyclophosphamide Fudarabine IL-2	1-3 ×108	PR	12
9	CD28 + CD28+ CD3	autologous	6-18 day	Gammaretrovirus	OKT3 + IL-2	5-6 weeks	8CLL 1ALL	4 NA, Cyclophosphamide	0.4-3.0 ×107/kg	3NEc, 1Died, 1CR, 1PD, 3SD	10
3	CD8-CD8 + 4-1BB + CD3	autologous	10 day	Lentivirus	CD3/28 beads	6 month	CLL	Pentostatin cyclophosphamide	1.46 × 105/kg 1.0-1.6 × 107/kg	2CR, 1PR	6
6	IgG-CD28 + CD3/CD28-CD3	autologous	6-8 day	Gammaretrovirus	OKT3 + IL-2	6 weeks	lymphoma	NA	2-10 ×107/m2	6PR	13
8	CD28 + CD28+ CD3	autologous	24 day	Gammaretrovirus	OKT3 + IL-2	< 20 day or 8 weeks	4lymphoma 4CLL	Cyclophosphamide, Fudarabine, IL-2	0.3-2.8×107/kg	1Died, 5PR, 1CR, 1SD	11
5	CD28 + CD28+ CD3	autologous	14 day	Gammaretrovirus	CD3/28 beads	3-8 weeks	ALL	Cyclophosphamide	1.4-3.2 ×108/kg	5CR	15
8	IgG-CD28 + CD28+ CD3	allogeneic	5-6 week	Gammaretrovirus	Ad. Pp65+ EBV-LCLs+ IL-2	1-12 weeks	ALL	NA	1.5-12× 107/m2	1CR, 1PR, 2CCR, 1SD, 3PD	3
2	CD8-CD8+ 4-1BB+ CD3	autologous	10 day	Lentivirus	CD3/28 beads	6 month	ALL	NA or Cyclophosphamide	0.14-1.2 × 107/kg	2CR	4
10	CD28 + CD28+ CD3	allogeneic	8 day	Gammaretrovirus	OKT3 + IL-2	1 month	4 CLL 6 lymphoma	NA	1 × 106 /kg	6SD, 2PD, 1CR, 1PR	2
11	lgG+ CD 28	autologous	14 day	Gammaretrovirus	CD3/28 beads	2-3 month	ALL	Cyclophosphamide	3 × 106/kg	9CR, 2NE	16
15	CD28+ TCR	autologous	10 day	Gammaretrovirus	OKT3 + IL-2	<75 day	4 CLL, 11 lymphoma	CyclophosphamideFudarabine	5 × 106/kg	4PR, 8CR, 1SD, 2NE	7
21	lgG+ CD3+CD28	autologous	11 day	retroviruses	CD3/28 beads	68 day	20 ALL, 1 lymphoma	Fudarabine Cyclophosphamide	1-3 × 106/kg	3SD, 4PD, 13CR, CiR	8
30	CD8-CD8 + 4-1BB + CD3	autologous	10 day	Lentivirus	CD3/28 beads	up to 11 month	ALL	Fudarabine Cyclophosphamide	0.76-20 × 10 6/kg	27CR, 3NE	14

^aNo.= patients in clinical trial received CD19-CAR T cells;

^bDose of infused T cells;

^cNE= no response and no evaluation